Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Sep 30, 2022 6:28pm

117 Views

Post# 34998685

AGN.c receives approval to conduct DMT study in the Netherla

AGN.c receives approval to conduct DMT study in the Netherlands.

https://twitter.com/big_gonads/status/1575896549456220160

Phase 1 of this study will examine intravenous DMT for the treatment of ischemic stroke. “DMT’s effects have opened an extraordinarily promising set of potential therapeutic applications for Algernon to explore,” said Rick Strassman.

<< Previous

Bullboard Posts

Next >>

Nine Mile Metals completes acquisition of 3 properties